Enhabit (EHAB) Stock Price, News & Analysis

Company Overview

Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was founded in 1998 and is based in Dallas, Texas.

Key Stats

• Today's Range: $7.94 to $8.12
• 50-Day Range: $6.53 to $10.22
• 52-Week Range: $6.47 to $10.90
• Volume: 180,985 shs
• Average Volume: 456,515 shs
• Market Capitalization: $410.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.67
• Consensus Rating: Hold

Enhabit Stock Analysis - MarketRank™

Enhabit scored higher than 35% of companies evaluated by MarketBeat, and ranked 745th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

Enhabit has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Enhabit has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 31.82%

Earnings Growth

Earnings for Enhabit are expected to grow by 31.82% in the coming year, from $0.22 to $0.29 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Enhabit is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Enhabit is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Enhabit has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.48% of the float of Enhabit has been sold short.

Short Interest Ratio / Days to Cover

Enhabit has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Enhabit has recently increased by 10.14%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Enhabit does not currently pay a dividend.

Dividend Growth

Enhabit does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.48% of the float of Enhabit has been sold short.

Short Interest Ratio / Days to Cover

Enhabit has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Enhabit has recently increased by 10.14%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

Enhabit has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.

Search Interest

Only 1 people have searched for EHAB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Enhabit insiders have bought more of their company's stock than they have sold. Specifically, they have bought $76,400.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 3.40% of the stock of Enhabit is held by insiders.

EHAB Stock Analysis - Frequently Asked Questions

How have EHAB shares performed this year?

Enhabit's stock was trading at $7.81 at the start of the year. Since then, EHAB shares have increased by 3.6% and is now trading at $8.0950.

How were Enhabit's earnings last quarter?

Enhabit, Inc. (NYSE:EHAB) issued its quarterly earnings results on Wednesday, August, 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.03. The business had revenue of $266.10 million for the quarter, compared to analysts' expectations of $263.39 million. Enhabit had a positive trailing twelve-month return on equity of 2.72% and a negative net margin of 12.84%.
Read the conference call transcript.

Who are Enhabit's major shareholders?

Top institutional shareholders of Enhabit include 8 Knots Management LLC (7.60%), AREX Capital Management LP (4.90%), Systematic Financial Management LP (3.83%) and Paradice Investment Management LLC (3.43%). Insiders that own company stock include Ryan Solomon, Jeffrey Bolton, Stuart M Mcguigan, Ronald Leroy Langham Jr, L Edward Shaw Jr, Erin Hoeflinger, Gregory S Rush and Collin Mcquiddy.
View institutional ownership trends.

How do I buy shares of Enhabit?

Shares of EHAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Enhabit own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Enhabit investors own include Alphabet (GOOG), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX), Home Depot (HD) and Meta Platforms (META).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 8/20/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NYSE:EHAB
• CIK: 1803737
• Web: www.ehab.com
• Phone: 214-239-6500
• Fax: N/A
• Employees: 10,700
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Enhabit: $8.67
• High Price Target: $9.50
• Low Price Target: $8.00
• Potential Upside/Downside: +8.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.67)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 36.48
• P/E Growth: N/A
• Net Income: -$156.20 million
• Net Margins: -12.84%
• Pretax Margin: -12.17%
• Return on Equity: 2.72%
• Return on Assets: 1.25%

Debt

• Debt-to-Equity Ratio: 0.79
• Current Ratio: 1.57
• Quick Ratio: 1.57

Sales & Book Value

• Annual Sales: $1.03 billion
• Price / Sales: 0.39
• Cash Flow: $4.12 per share
• Price / Cash Flow: 1.95
• Book Value: $11.40 per share
• Price / Book: 0.70

Miscellaneous

• Outstanding Shares: 50,690,000
• Free Float: 48,967,000
• Market Cap: $406.79 million
• Optionable: Optionable
• Beta: 1.68